immunohistochemical studies to react with osteosarcomas, were labelled with 1251 or 1311 and evaluated for their ability to localise to human osteogenic sarcoma xenografts after intravenous injection. The radiolabelled TP-1 and TP-3 MoAbs had immunoreactive fractions of 70% and 67%, respectively, and bound to target cells with binding constants of 8.5 x 108 M -1 and 4.0 x 109 M -1, respectively. After injection of labelled TP-3 IgG, -16% of the dose x g-tissue was found in the tumour after 24 hours. Maximum tumour/blood radioactivity ratios of 6-7 were achieved 3-4 days after antibody injection, while the ratios for the normal tissues were < 1. The tumours could be clearly visualised by whole-body gamma scintigraphy without the need for subtraction techniques. The TP-1 IgG accumulated to a large extent also in the spleen. Hence, with this antibody the tumour was less well delineated from the adjacent normal tissues. However, the F(ab')2 fragments, derived from the TP-1 IgG, gave tumour/blood ratios up to -40 after 3-4 days and yielded sharp gamma scintigrams of the tumour. Specificity of the antibody localisation was indicated by the lack of accumulation in a contralateral melanoma xenograft and the failure of 2 isotype-matched irrelevant MoAbs to localise to the sarcomas. With the F(ab')2 fragments satisfactory images could be obtained already after 16 hours. The results suggest that this preparation may be useful in clinical radioimmunodetection of osteogenic sarcomas.
In recent years considerable efforts have been made to utilize human osteosarcoma cells, were produced as previously monoclonal antibodies, MoAbs, in diagnosis and therapy of described . The antibodies were purified human cancers (see Schlom, 1986) . Immunoscintigraphy of from ascites by affinity chromatography on a protein Atumours in patients has primarily been successful in Sepharose column (Pharmacia, Uppsala, Sweden). F(ab')2 melanoma (Larson et al., 1985; Siccardi et al., 1986) , fragments of TP-1 were obtained by digestion with pepsin colorectal cancer (Mach et al., 1980; Mach et al., 1983;  for 8 h using a pepsin/IgG ratio of 3/100 (weight/weight) Chatal et al., 1985) , and ovarian cancer (Epenetos et al., (Parham, 1983 . So far less work has been reported on the The purity of the antibody preparations was checked by disgnostic use of MoAbs in sarcoma patients (Armitage et polyacrylamide gel electrophoresis (Laemmli, 1970) , and by al., 1986; Greager et al., 1986) . However, preclinical studies ion exchange chromatography using FPLC (Pharmacia). have been carried out on nude mice bearing xenografts of
The antibodies were labelled with 1251 or 1311 by the human osteosarcoma (Pimm et al., 1982 ; Nakamura et al., lodo-Gen method (Fraker & Speck, 1978) . The labelled 1984) and a soft tissue sarcoma (Brown et al., 1985) .
proteins were purified by gel filtration on Sephadex G25 Recently we have isolated 2 new antisarcoma MoAbs, (Pharmacia) . More than 95% of the eluted activity was TP-1 and TP-3 . In immunohistochemical precipitated by 10% trichloroacetic acid. The specific activity studies these antibodies were found to be highly specific; ranged from 20 to 30yCi/,ug in different preparations. they reacted only with certain subgroups of sarcomas, viz.
The immunoreactive fraction of the radiolabelled MoAbs osteosarcomas, malignant fibrous histiocytomas and some was determined by measuring the binding of antibody to unclassified sarcomas, but not with the other types of human increasing concentrations of the OHS osteosarcoma cells and tumours tested. Also they failed to bind to a wide range of carrying out linear extrapolation to binding at infinite normal adult and foetal tissues. Only in the case of proximal antigen excess, as described by Lindmo et al. (1984 Scintigraphic analysis
Inverse of cell concentration (ml 10-6)
The localisation of the antibodies to the tumour was studied Lindmo et al. (1984) tions in their ability to accumulate and retain radioactivity, from plots as shown in Figure 1 . The immunoreactive as is evident from the standard deviations. fraction of the TP-3 antibody was -67%. In similar
The tissue distribution of the radioactivity and the change experiments the immunoreactive fractions of TP-1 and the with time varied considerably for the different preparations corresponding F(ab')2 fragments were found to be 70%, and (Table I ). In the case of TP-3, the activity in the tumour was 55%, respectively. retained essentially unchanged for -3 days, whereupon it Scatchard analysis showed that TP-1 and TP-3 MoAbs declined markedly. In the liver and kidney, the activities had binding constants of about 8.5 x 108 M-1 and decreased only moderately during the first few days, and 4.0 x 109 M-1, respectively (data not shown). These values then rather abruptly from day 3 to day 4. The radioactivity are well in excess of those estimated in a theoretical study in the blood decreased sharply from day 2 on. The results (Kennel et al., 1983) to be sufficient for antibodies to be imply that the tumour/blood ratio increased during the first useful in drug targeting or tumour imaging.
3 days, as will be discussed below. In the case of TP-l IgG, a high spleen radioactivity was MoAbs, TP-0 and UPC-10, were used. With the TP-0 (IgG found. In fact, in several animals the spleen radioactivity 2b), the results were in agreement with expectation inasmuch exceeded that found in the tumour. Also the activity in the as the tissue/blood ratios were <I for both tumour and liver was higher than after administration of the TP-3.
normal tissues (not shown). Also in the case of UPC-10 (IgG Conceivably, post-labelling aggregations could have 2a), there was no accumulation of radioactivity in the contributed to the odd splenic uptake. However, this possitumour. With this antibody, one of the 4 tumour-bearing bility is considered unlikely, as in some animals receiving mice showed an increased spleen/blood radioactivity ratio the same preparation no abnormal splenic accumulation (1.9). The reason for this finding is not obvious. In all other was seen.
animals the tissue/blood ratios were close to or < 1. Since unspecific uptake of antibodies in spleen and liver may be associated with the Fc portion of IgG, we prepared Scintigraphic analysis the F(ab')2 from the TP-1 IgG. With the fragments there On the basis of the results in Table I and Figure 2 it was was no increased uptake in spleen and liver. The radioantted the visultin TableoIca Figraft by activity in the tumour declined more rapidly than after anticipated that visualization of osteosarcoma xenografts by administration of the IgG preparation. However, the activity gamma scintigraphy should be feasible, at least with TP-3 in the blood disappeared at a much faster rate. For this IgG and the TP-1 F(ab')2 fragments reason the tumour/blood radioactivity ratio, one significant Gamma camera images were recorded at different times parameter in imaging, initially increased strongly with time, after i.v. injection of the different antibodies. In Figure 3 are as illustrated below, shown scintigrams taken after 2 days. At this time the
The tissue/blood radioactivity ratios for tumour, spleen, absolute amounts of radioactivity in the tumour were still liver and kidney are shown in Figure 2 . To take into account appreciable (Table I ) and the tumour/blood radioactivity the large variations between individual animals in the ratios were relatively high (Figure 2 ). It is apparent that with radioactivity of both tissues and blood, we computed, for TP-3 IgG (left panel), a distinct image of the tumour was each animal, the radioactivity ratios and plotted the mean of obtained.
the values thus obtained. It is seen (Figure 2 , left panel) that Also with TP-1 IgG, the tumour was clearly visible, but in the case of TP-3, the tumour/blood radioactivity ratio the discrimination between the tumour and adjacent tissues increased up to 6 in the course of 3 days and then was less satisfactory (middle panel) than with TP-3, as remained essentially constant. For the other tissues, the expected from the tissue distribution studies shown in Table   ratios were in all cases <1 and in most cases <0.5.
I. In a separate experiment in which the animals carried a
The striking differences in in ou bet the whole sarcoma in one flank and a melanoma in the other one, only TP-1gi and the corresponding F(ab')2 fragments becomes the sarcoma was visualised (not shown). Figure 3 shows the tumour/blood ratio deereased with time after day 1, and that after 2 days the radioactivity was present almost the spleen/blood ratio was very high. In contrast, with the exclusively in the tumour. Due to the rapid clearance of F(ab')2 fragments, the tumour/blood ratio increased strongly labelled material from the blood, satisfactory images could with time up to about 40 after 4 days, while concurrently the be obtained already after 16h, as shown in Figure 4 .
spleen/blood ratio increased up to 3 only. In the latter case, the kidney/blood ratio was higher than with the whole Discussion antibody, probably due to renal elimination of labelled material. For heart, lung, bone, and brain tissues (not The results reported in this preclinical study show that the 2 shown), the ratios were considerably < 1. techniques. In fact, the accumulation of antibody radioIt is of interest that the two anti-sarcoma MoAbs which activity in the tumour, relative to that in blood and normal bind to the same antigen (Bruland, manuscript in tissues, was considerably higher in the present study than in preparation), were found to differ considerably in their earlier investigations in which anti-sarcoma antibodies were biological properties and potential clinical usefulness. After administered to sarcoma-bearing athymic mice. Thus, injection of TP-3, the tumour/blood radioactivity ratio Nakamura et al. (1984) found tumour/blood radioactivity inrased up to 6-7 on day 3, and with this antibody the ratios up to 4.3. 5-7 days after injection of antibodies Ost 6 sarcoma xenografts could easily be visualized by immuno-and Ost 7, and Brown et al. (1985) observed tumour/blood scintigraphy. In contrast, after administration of the other ratios of 2.2-3.4 on day 7 with the antibody 19-24. Also the MoAb, TP-I IgG, the tumour/blood radioactivity ratio tumour/blood ratios observed by Pimm et al. (1982) with the deceae from day 1 on, and appreciable radioactivity wvas antibody 79IT/36 were considerably lower than those found loclised in the spleen. For this reason the scintigraphic in the preset workc.
images of the sarcomas were poorly defined with inadequate lThe demonstration of a high and semingly seific uptakce discrimination between the tumour tissue and the spenliver of the labelld MoAbs in human tulmour xeogafts in nude region.
mice is, however, no assurance that sucsfl imaging can be achieved in patients. (Brown et al., 1984; Pimm et al., 1982) and showed less tissue specificity (Pim et al., 1982) than our antibodies. On this basis the present results seem sufficiently encouraging to warrant explorative studies of TP-3 IgG and TP-1 F(ab')2 in humans. The demonstration that sharp gamma-images could be obtained already after 16 h, opens the possibility of using radionuclides with short half-lives, such as 99mTc, and 1231, which have excellent physical properties for the purpose of imaging (Epenetos et al., 1982; Granowska et al., 1986 ). Recently we have initiated immunoscintigraphic studies using 123I-labelled TP-1 F(ab')2 fragments in patients with metastatic osteogenic sarcoma.
